Interleukin Genetics

ilgenetics.com

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. The products empower individuals and their healthcare providers to manage prevention and treatment of chronic diseases through genetics-based insights and actionable guidance. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program and its Inherent Health® line of genetic tests.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

news image

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More

MEDICAL

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

news image

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

Labiotech.eu | January 27, 2020

news image

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More
news image

PHARMABCINE EXPANDS PARTNERSHIP WITH SAMSUNG BIOLOGICS FOR PMC-403

PharmAbcine Inc. | September 21, 2020

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support. PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibo...

Read More
news image

MEDICAL

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More
news image

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

Labiotech.eu | January 27, 2020

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More
news image

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us